These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30343173)

  • 21. [Second-line treatment for metastatic or locally advanced gastric cancer].
    Li KC; Cheng SY; Du J; Li J
    Zhonghua Zhong Liu Za Zhi; 2016 Oct; 38(10):721-724. PubMed ID: 27784452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes.
    Gill S; Dowden S; Colwell B; Collins LL; Berry S
    Cancer Treat Rev; 2014 Dec; 40(10):1171-81. PubMed ID: 25458604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted therapy in gastric cancer.
    Thiel A; Ristimäki A
    APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
    Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
    Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant therapy for oesophagogastric cancer.
    Lordick F; Stein HJ; Peschel C; Siewert JR
    Br J Surg; 2004 May; 91(5):540-51. PubMed ID: 15122603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
    Adam J; Tomasic G; Robert C
    Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
    Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E
    Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
    Bang YJ
    J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
    Villaruz LC; Socinski MA
    Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis.
    Ter Veer E; van Kleef JJ; Schokker S; van der Woude SO; Laarman M; Haj Mohammad N; Sprangers MAG; van Oijen MGH; van Laarhoven HWM
    Eur J Cancer; 2018 Nov; 103():214-226. PubMed ID: 30268922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer.
    Murphy AG; Kelly RJ
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):485-498. PubMed ID: 28501089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
    Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and Future Therapies for Advanced Gastric Cancer.
    Davidson M; Okines AF; Starling N
    Clin Colorectal Cancer; 2015 Dec; 14(4):239-50. PubMed ID: 26524924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.
    Yu L; Wang Y; Shao S; Yang M; Niu H; Yu Q; Wang X
    Tumori; 2015; 101(5):549-54. PubMed ID: 26045125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular markers for gastric adenocarcinoma: an update.
    Anderson C; Nijagal A; Kim J
    Mol Diagn Ther; 2006; 10(6):345-52. PubMed ID: 17154651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?
    De Mello RA; Castelo-Branco L; Castelo-Branco P; Pozza DH; Vermeulen L; Palacio S; Salzberg M; Lockhart AC
    Am Soc Clin Oncol Educ Book; 2018 May; 38():249-261. PubMed ID: 30231398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer.
    Schønnemann KR; Mortensen MB; Bjerregaard JK; Fristrup C; Pfeiffer P
    Acta Oncol; 2014 Mar; 53(3):385-91. PubMed ID: 23957622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials.
    Franco P; Arcadipane F; Strignano P; Spadi R; Trino E; Martini S; Iorio GC; Satolli MA; Airoldi M; Romagnoli R; Camandona M; Ricardi U
    Med Oncol; 2017 Mar; 34(3):40. PubMed ID: 28176241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current diagnosis and future impact of micrometastases for therapeutic strategies in adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.
    Kutup A; Yekebas EF; Izbicki JR
    Recent Results Cancer Res; 2010; 182():115-25. PubMed ID: 20676876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A reliable risk score for stage IV esophagogastric cancer.
    Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
    Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.